MedTrace Logo

SeroCovid<19: Covid-19 Seroconversion in Tertiary Pediatric Patients

NCT04615000 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 362

Last updated 2022-07-01

No results posted yet for this study

Summary

Children are relatively spared from the direct clinical impact of COVID-19. Pediatric patients with regular follow-up at tertiary pediatric centres and presenting one or more chronic conditions might be at increased risk for severe COVID-19. With a prospective seroprevalence study, we aim to study COVID-19 incidence, disease course and risk factors associated with SARS-CoV-2 infection in this specific context.

Conditions

  • Covid19
  • Children, Only

Interventions

DIAGNOSTIC_TEST

SARS-CoV-2 serological assessment (IgG)

Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval

Sponsors & Collaborators

  • University Ghent

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Filomeen Haerynck, MD, PhD · University Hospital, Ghent

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04615000 on ClinicalTrials.gov